Integrated Multi-Omics Profiling to Characterize Molecular Subtypes and Reveal Potential Therapeutic Strategies for Colorectal Cancer

Abstract

Colorectal cancer (CRC) is a complex and heterogeneous disease with limited effective treatment options. To investigate the molecular features and potential therapeutic strategies for CRC patients, including both early-onset colorectal cancer (EOCRC) and late-onset colorectal cancer (LOCRC) cases, a comprehensive multi-omics approach was employed. Whole exome sequencing (WES), RNA sequencing (RNA-seq), and proteomic and phosphoproteomic profiling were performed on paired tumor and normal adjacent tissue (NAT) from 144 CRC patients, totaling 672 samples. Three distinct molecular subtypes were identified, each exhibiting unique clinical prognoses and molecular characteristics. The S_I subtype was associated with the worst prognosis and a greater prevalence of EOCRC. Moreover, it exhibited a higher stromal score, characterized by increased infiltration of fibroblasts, mesenchymal stem cells, and adipocytes, when compared with the S_II and S_III subtypes. Additionally, the S_II subtype showed a higher immune score. Drug testing using cell lines and patient-derived three-dimensional (3D) bioprinted models revealed that S_I tumors were more responsive to Alisertib, suggesting subtype-specific therapeutic potential. Our study characterized the multi-omics landscape of CRC, offering critical insights into its molecular heterogeneity. These findings enhance our understanding of the molecular mechanisms underlying CRC and contribute to the development of personalized treatment strategies.

Keywords

colorectal cancer (CRC) / molecular subtype / multi-omics / therapeutic strategy

References

[1] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209–249.

[2] E. Morgan, M. Arnold, A. Gini, et al., “Global Burden of Colorectal Cancer in 2020 and 2040: Incidence and Mortality Estimates From GLOBOCAN,” Gut 72, no. 2 (2023): 338–344.

[3] M. Giannakis and K. Ng, “A Common Cancer at an Uncommon Age,” Science 379, no. 6637 (2023): 1088–1090.

[4] M. R. Saraiva, I. Rosa, and I. Claro, “Early-Onset Colorectal Cancer: A Review of Current Knowledge,” World Journal of Gastroenterology 29, no. 8 (2023): 1289–1303.

[5] X. H. Gao, J. Li, L. J. Liu, et al., “Trends, Clinicopathological Features, Surgical Treatment Patterns and Prognoses of Early-Onset Versus Late-Onset Colorectal Cancer: A Retrospective Cohort Study on 34067 Patients Managed From 2000 to 2021 in a Chinese Tertiary Center,” International Journal of Surgery 104 (2022): 106780.

[6] A. M. Zaborowski, B. Murphy, B. Creavin, et al., “Clinicopathological Features and Oncological Outcomes of Patients With Young-Onset Rectal Cancer,” British Journal of Surgery 107, no. 5 (2020): 606–612.

[7] E. Dekker, P. J. Tanis, J. L. A. Vleugels, P. M. Kasi, and M. B. Wallace, “Colorectal Cancer,” Lancet 394, no. 10207 (2019): 1467–1480.

[8] M. Song and A. T. Chan, “Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention,” Clinical Gastroenterology and Hepatology 17, no. 2 (2019): 275–289.

[9] L. H. Biller and D. Schrag, “Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review,” JAMA 325, no. 7 (2021): 669–685.

[10] C. J. Punt, M. Koopman, and L. Vermeulen, “From Tumour Heterogeneity to Advances in Precision Treatment of Colorectal Cancer,” Nature Reviews Clinical Oncology 14, no. 4 (2017): 235–246.

[11] T. André, K. K. Shiu, T. W. Kim, et al., “Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer,” New England Journal of Medicine 383, no. 23 (2020): 2207–2218.

[12] A. Kanani, T. Veen, and K. Søreide, “Neoadjuvant Immunotherapy in Primary and Metastatic Colorectal Cancer,” British Journal of Surgery 108, no. 12 (2021): 1417–1425.

[13] K. Ganesh, Z. K. Stadler, A. Cercek, et al., “Immunotherapy in Colorectal Cancer: Rationale, Challenges and Potential,” Nature Reviews Gastroenterology & Hepatology 16, no. 6 (2019): 361–375.

[14] Y. H. Xie, Y. X. Chen, and J. Y. Fang, “Comprehensive Review of Targeted Therapy for Colorectal Cancer,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 22.

[15] T. Wang, L. Wu, S. Wang, X. Shi, H. Liu, and W. Deng, “Chang Wei Qing Decoction Enhances the Anti-Tumor Effect of PD-1 Inhibitor Therapy by Regulating the Immune Microenvironment and Gut Microbiota in Colorectal Cancer,” Chinese Journal of Natural Medicines 21, no. 5 (2023): 333–345.

[16] Y. Jiang, A. Sun, Y. Zhao, et al., “Proteomics Identifies New Therapeutic Targets of Early-Stage Hepatocellular Carcinoma,” Nature 567, no. 7747 (2019): 257–261.

[17] Q. Zhao, F. Wang, Y. X. Chen, et al., “Comprehensive Profiling of 1015 Patients' exomes Reveals Genomic-Clinical Associations in Colorectal Cancer,” Nature Communications 13, no. 1 (2022): 2342.

[18] J. Y. Xu, C. Zhang, X. Wang, et al., “Integrative Proteomic Characterization of human Lung Adenocarcinoma,” Cell 182, no. 1 (2020): 245–261.

[19] J. Guinney, R. Dienstmann, X. Wang, et al., “The Consensus Molecular Subtypes of Colorectal Cancer,” Nature Medicine 21, no. 11 (2015): 1350–1356.

[20] B. Zhang, J. Wang, X. Wang, et al., “Proteogenomic Characterization of Human Colon and Rectal Cancer,” Nature 513, no. 7518 (2014): 382–387.

[21] C. Li, Y.-D. Sun, G.-Y. Yu, et al., “Integrated Omics of Metastatic Colorectal Cancer,” Cancer Cell 38, no. 5 (2020): 734–747. e739.

[22] Z. Hu, Z. Wu, W. Liu, et al., “Proteogenomic Insights Into Early-Onset Endometrioid Endometrial Carcinoma: Predictors for Fertility-Sparing Therapy Response,” Nature Genetics 56, no. 4 (2024): 637–651.

[23] X. Guo, W. Zhou, J. Jin, et al., “Integrative Multi-Omics Analysis Identifies Transmembrane p24 Trafficking Protein 1 (TMED1) as a Potential Prognostic Marker in Colorectal Cancer,” Biology (Basel) 13, no. 2 (2024): 83.

[24] Q. Liu, J. Zhang, C. Guo, et al., “Proteogenomic Characterization of Small Cell Lung Cancer Identifies Biological Insights and Subtype-Specific Therapeutic Strategies,” Cell 187, no. 1 (2024): 184–203.

[25] Q. Zhang, X. Xu, D. Jiang, et al., “Integrated Proteogenomic Characterization of Ampullary Adenocarcinoma,” Cell Discovery 11, no. 1 (2025): 2.

[26] Q. Zhang, Q. Huang, Z. Cheng, et al., “Exploring the Mechanism of Xiaoaiping Injection Inhibiting Autophagy in Prostate Cancer Based on Proteomics,” Chinese Journal of Natural Medicines 23, no. 1 (2025): 64–76.

[27] S. Li, L. Yuan, Z.-Y. Xu, et al., “Integrative Proteomic Characterization of Adenocarcinoma of Esophagogastric Junction,” Nature Communications 14, no. 1 (2023): 778.

[28] V. M. Bui, C. Mettling, J. Jou, and H. S. Sun, “Genomic Amplification of Chromosome 20q13.33 Is the Early Biomarker for the Development of Sporadic Colorectal Carcinoma,” BMC Medical Genomics 13, no. 10 (2020): 149.

[29] L. Yi, L. Yi, Q. Liu, and C. Li, “Downregulation of NSD3 (WHSC1L1) Inhibits Cell Proliferation and Migration via ERK1/2 Deactivation and Decreasing CAPG Expression in Colorectal Cancer Cells,” OncoTargets and Therapy 12 (2019): 3933–3943.

[30] H. Kobayashi, K. A. Gieniec, T. R. M. Lannagan, et al., “The Origin and Contribution of Cancer-Associated Fibroblasts in Colorectal Carcinogenesis,” Gastroenterology 162, no. 3 (2022): 890–906.

[31] Y. Hoshida, “Nearest Template Prediction: A Single-Sample-Based Flexible Class Prediction With Confidence Assessment,” PLoS ONE 5, no. 11 (2010): e15543.

[32] J. Zhu, T. Long, L. Gao, et al., “RPL21 Interacts With LAMP3 to Promote Colorectal Cancer Invasion and Metastasis by Regulating Focal Adhesion Formation,” Cellular & Molecular Biology Letters 28, no. 1 (2023): 31.

[33] C. Gu, X. Wang, T. Long, et al., “FSTL1 Interacts with VIM and Promotes Colorectal Cancer Metastasis via Activating the Focal Adhesion Signalling Pathway,” Cell Death & Disease 9, no. 6 (2018): 654.

[34] K. Zeng, W. Li, Y. Wang, et al., “Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-Mediated Ferroptosis in Colorectal Cancer,” Advanced Science 10, no. 25 (2023): e2301088.

[35] M. Arora, J. Moser, T. E. Hoffman, et al., “Rapid Adaptation to CDK2 Inhibition Exposes Intrinsic Cell-Cycle Plasticity,” Cell 186, no. 12 (2023): 2628–2643.

[36] W. Chen, X. Zhuang, Y. Chen, et al., “Recent Advances in Regulating the Cell Cycle Through Inhibiting CDKs for Cancer Treatment,” Chinese Journal of Natural Medicines 23, no. 3 (2025): 286–298.

[37] Z. D. Liu, Y. H. Shi, Q. C. Xu, et al., “CSNK2A1 confers Gemcitabine Resistance to Pancreatic Ductal Adenocarcinoma via Inducing Autophagy,” Cancer Letters 585 (2024): 216640.

[38] F. Zhang, L. Qi, Q. Feng, et al., “HIPK2 phosphorylates HDAC3 for NF-κB Acetylation to Ameliorate Colitis-Associated Colorectal Carcinoma and Sepsis,” Proceedings of the National Academy of Sciences of the United States of America 118, no. 28 (2021): e2021798118.

[39] W. Yang, J. Soares, P. Greninger, et al., “Genomics of Drug Sensitivity in Cancer (GDSC): A Resource for Therapeutic Biomarker Discovery in Cancer Cells,” Nucleic Acids Research 41 (2013): 955–961.

[40] S. M. Corsello, R. T. Nagari, R. D. Spangler, et al., “Discovering the Anti-Cancer Potential of Non-Oncology Drugs by Systematic Viability Profiling,” Nature Cancer 1, no. 2 (2020): 235–248.

[41] P. Geeleher, N. Cox, and R. S. Huang, “pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response From Tumor Gene Expression Levels,” PLoS ONE 9, no. 9 (2014): e107468.

[42] M. E. Ritchie, B. Phipson, D. Wu, et al., “limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies,” Nucleic Acids Research 43, no. 7 (2015): e47.

[43] J. M. Bader, N. Deigendesch, M. Misch, M. Mann, A. Koch, and F. Meissner, “Proteomics Separates Adult-Type Diffuse High-Grade Gliomas in Metabolic Subgroups Independent of 1p/19q Codeletion and Across IDH Mutational Status,” Cell Reports Medicine 4, no. 1 (2023): 100877.

[44] W. Chong, X. Zhu, H. Ren, et al., “Integrated Multi-Omics Characterization of KRAS Mutant Colorectal Cancer,” Theranostics 12, no. 11 (2022): 5138–5154.

[45] S. Tang, Y. Wang, R. Luo, et al., “Proteomic Characterization Identifies Clinically Relevant Subgroups of Soft Tissue Sarcoma,” Nature Communications 15, no. 1 (2024): 1381.

[46] Y. Wang, H. Xu, B. Zhu, Z. Qiu, and Z. Lin, “Systematic Identification of the Key Candidate Genes in Breast Cancer Stroma,” Cellular & Molecular Biology Letters 23, no. 1 (2018): 44.

[47] K. Lin, Y. Zhao, Y. Tang, Y. Chen, M. Lin, and L. He, “Collagen I-Induced VCAN/ERK Signaling and PARP1/ZEB1-Mediated Metastasis Facilitate OSBPL2 Defect to Promote Colorectal Cancer Progression,” Cell Death & Disease 15, no. 1 (2024): 85.

[48] X. Mao, J. Xu, W. Wang, et al., “Crosstalk Between Cancer-associated Fibroblasts and Immune Cells in the Tumor Microenvironment: New Findings and Future Perspectives,” Molecular Cancer 20, no. 1 (2021): 131.

[49] M. S. Carlino, J. Larkin, and G. V. Long, “Immune Checkpoint Inhibitors in Melanoma,” Lancet 398, no. 10304 (2021): 1002–1014.

[50] A. Van Weverwijk and K. E. De Visser, “Mechanisms Driving the Immunoregulatory Function of Cancer Cells,” Nature Reviews Cancer 23, no. 4 (2023): 193–215.

[51] Y. Feng, Y. Li, F. Ma, et al., “Notoginsenoside Ft1 Inhibits Colorectal Cancer Growth by Increasing CD8+ T Cell Proportion in Tumor-Bearing Mice Through the USP9X Signaling Pathway,” Chinese Journal of Natural Medicines 22, no. 4 (2024): 329–340.

[52] A. V. Leopold, K. G. Chernov, and V. V. Verkhusha, “Optogenetically Controlled Protein Kinases for Regulation of Cellular Signaling,” Chemical Society Reviews 47, no. 7 (2018): 2454–2484.

[53] L. Liu, Y. Liu, S. Zhang, et al., “Celastrol Promotes Apoptosis of Breast Cancer MDA-MB-231 Cells by Targeting HSDL2,” Acupuncture and Herbal Medicine 4, no. 1 (2024): 92–101.

[54] S. Klaeger, S. Heinzlmeir, M. Wilhelm, et al., “The Target Landscape of Clinical Kinase Drugs,” Science 358, no. 6367 (2017): 4368.

[55] L. Castelo-Soccio, H. Kim, M. Gadina, P. L. Schwartzberg, A. Laurence, and J. J. O'shea, “Protein Kinases: Drug Targets for Immunological Disorders,” Nature Reviews Immunology 23, no. 12 (2023): 787–806.

[56] C. Borgo, C. D'amore, S. Sarno, M. Salvi, and M. Ruzzene, “Protein Kinase CK2: A Potential Therapeutic Target for Diverse Human Diseases,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 183.

[57] M. J. Borad, L. Y. Bai, D. Richards, et al., “Silmitasertib plus Gemcitabine and Cisplatin First-Line Therapy in Locally Advanced/Metastatic Cholangiocarcinoma: A Phase 1b/2 Study,” Hepatology 77, no. 3 (2023): 760–773.

[58] M. Tang, Q. Xie, R. C. Gimple, et al., “Three-dimensional Bioprinted Glioblastoma Microenvironments Model Cellular Dependencies and Immune Interactions,” Cell Research 30, no. 10 (2020): 833–853.

[59] R. Du, C. Huang, K. Liu, X. Li, and Z. Dong, “Targeting AURKA in Cancer: Molecular Mechanisms and Opportunities for Cancer Therapy,” Molecular Cancer 20, no. 1 (2021): 15.

[60] A. Prestipino and R. Zeiser, “Clinical Implications of Tumor-Intrinsic Mechanisms Regulating PD-L1,” Science Translational Medicine 11, no. 478 (2019): 4810.

[61] X. Li, C. Gong, A. Naeem, et al., “Priming Immunity via Herbal Components and Their Nanomedicines for the Treatment of Cancer,” Acupuncture and Herbal Medicine 4, no. 4 (2024): 436–462.

[62] X. Wang, J. Huang, F. Liu, et al., “Aurora A Kinase Inhibition Compromises Its Antitumor Efficacy by Elevating PD-L1 Expression,” Journal of Clinical Investigation 133, no. 9 (2023): e161929.

[63] M. De Zuani, H. Xue, J. S. Park, et al., “Single-cell and Spatial Transcriptomics Analysis of Non-Small Cell Lung Cancer,” Nature Communications 15, no. 1 (2024): 4388.

[64] Y. Lei, R. Tang, J. Xu, et al., “Applications of Single-Cell Sequencing in Cancer Research: Progress and Perspectives,” Journal of Hematology & Oncology 14, no. 1 (2021): 91.

[65] J. Househam, T. Heide, G. D. Cresswell, et al., “Phenotypic Plasticity and Genetic Control in Colorectal Cancer Evolution,” Nature 611, no. 7937 (2022): 744–753.

[66] H. S. Bhatia, A. D. Brunner, F. Öztürk, et al., “Spatial Proteomics in Three-Dimensional Intact Specimens,” Cell 185, no. 26 (2022): 5040–5058.

[67] J. R. Wisniewski, A. Zougman, N. Nagaraj, and M. Mann, “Universal Sample Preparation Method for Proteome Analysis,” Nature Methods 6, no. 5 (2009): 359–362.

[68] S. Chen, Y. Zhou, Y. Chen, and J. Gu, “fastp: An Ultra-Fast All-in-One FASTQ Preprocessor,” Bioinformatics 34, no. 17 (2018): 884–890.

[69] H. Li and R. Durbin, “Fast and Accurate Long-Read Alignment With Burrows-Wheeler Transform,” Bioinformatics 26, no. 5 (2010): 589–595.

[70] D. Kim, B. Langmead, and S. L. Salzberg, “HISAT: A Fast Spliced Aligner With Low Memory Requirements,” Nature Methods 12, no. 4 (2015): 357–360.

[71] A. Roberts, C. Trapnell, J. Donaghey, J. L. Rinn, and L. Pachter, “Improving RNA-Seq Expression Estimates by Correcting for Fragment Bias,” Genome Biology 12, no. 3 (2011): R22.

[72] R. Bruderer, O. M. Bernhardt, T. Gandhi, et al., “Extending the Limits of Quantitative Proteome Profiling With Data-independent Acquisition and Application to Acetaminophen-Treated Three-Dimensional Liver Microtissues,” Molecular & Cellular Proteomics 14, no. 5 (2015): 1400–1410.

[73] B. C. Orsburn, “Proteome Discoverer-a Community Enhanced Data Processing Suite for Protein Informatics,” Proteomes 9, no. 1 (2021): 15.

[74] H. Li, B. Handsaker, A. Wysoker, et al., “The Sequence Alignment/Map Format and SAMtools,” Bioinformatics 25, no. 16 (2009): 2078–2079.

[75] A. Mckenna, M. Hanna, E. Banks, et al., “The Genome Analysis Toolkit: A Mapreduce Framework for Analyzing Next-Generation DNA Sequencing Data,” Genome Research 20, no. 9 (2010): 1297–1303.

[76] K. Cibulskis, M. S. Lawrence, S. L. Carter, et al., “Sensitive Detection of Somatic Point Mutations in Impure and Heterogeneous Cancer Samples,” Nature Biotechnology 31, no. 3 (2013): 213–219.

[77] K. Wang, M. Li, and H. Hakonarson, “ANNOVAR: Functional Annotation of Genetic Variants From High-Throughput Sequencing Data,” Nucleic Acids Research 38, no. 16 (2010): e164.

[78] A. Mayakonda, D. C. Lin, Y. Assenov, C. Plass, and H. P. Koeffler, “Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer,” Genome Research 28, no. 11 (2018): 1747–1756.

[79] Z. Gu, R. Eils, and M. Schlesner, “Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data,” Bioinformatics 32, no. 18 (2016): 2847–2849.

[80] M. D. Wilkerson and D. N. Hayes, “ConsensusClusterPlus: A Class Discovery Tool With Confidence Assessments and Item Tracking,” Bioinformatics 26, no. 12 (2010): 1572–1573.

[81] V. Boeva, T. Popova, K. Bleakley, et al., “Control-FREEC: A Tool for Assessing Copy Number and Allelic Content Using Next-Generation Sequencing Data,” Bioinformatics 28, no. 3 (2012): 423–425.

[82] C. H. Mermel, S. E. Schumacher, B. Hill, M. L. Meyerson, R. Beroukhim, and G. Getz, “GISTIC2.0 facilitates Sensitive and Confident Localization of the Targets of Focal Somatic Copy-Number Alteration in Human Cancers,” Genome Biology 12, no. 4 (2011): R41.

[83] X. Lu, J. Meng, Y. Zhou, L. Jiang, and F. Yan, “MOVICS: An R Package for Multi-Omics Integration and Visualization in Cancer Subtyping,” Bioinformatics 36, no. 22–23 (2021): 5539–5541.

[84] L. Li, D. Jiang, H. Liu, et al., “Comprehensive Proteogenomic Characterization of Early Duodenal Cancer Reveals the Carcinogenesis Tracks of Different Subtypes,” Nature Communications 14, no. 1 (2023): 1751.

[85] M. Harel, R. Ortenberg, S. K. Varanasi, et al., “Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence,” Cell 179, no. 1 (2019): 236–250.

[86] D. Aran, Z. Hu, and A. J. Butte, “xCell: Digitally Portraying the Tissue Cellular Heterogeneity Landscape,” Genome Biology 18, no. 1 (2017): 220.

[87] D. D. Wiredja, M. Koyutürk, and M. R. Chance, “The KSEA App: A Web-Based Tool for Kinase Activity Inference From Quantitative Phosphoproteomics,” Bioinformatics 33, no. 21 (2017): 3489–3491.

[88] P. V. Hornbeck, B. Zhang, B. Murray, J. M. Kornhauser, V. Latham, and E. Skrzypek, “PhosphoSitePlus, 2014: Mutations, PTMs and Recalibrations,” Nucleic Acids Research 43 (2015): 512–520.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.